Lipids improved by switching from ritonavir to cobicistat as a booster for darunavir

Michael Carter
Published: 06 September 2017


Switching from ritonavir to cobicistat is associated with significant improvements in cholesterol and triglyceride levels for people with dyslipidaemia, investigators from Spain report in HIV Medicine. Ritonavir was replaced with cobicistat to boost the protease inhibitor darunavir. Six months after the switch, cholesterol and triglycerides had significantly improved among people with lipid abnormalities at baseline.

“More than 50% of the total study population presented with dyslipidaemia at baseline,” comment the researchers. “A significant improvement in all lipid parameters, including HDL cholesterol, was seen 24 weeks after the switch in those subjects with hypercholesterolaemia at baseline, and triglyceride levels improved mainly in those who presented with hypertriglyceridaemia at baseline, while virological efficacy and immunological status were maintained after the replacement,” write the researchers. “These results indicate that replacement of ritonavir with cobicistat could decrease the percentage of subjects with dyslipidaemia associated with ART [antiretroviral therapy] and consequently cardiovascular risk.”

Cobicistat is an approved boosting agent for certain antiretroviral drugs, including the protease inhibitor darunavir (a co-formulation of the two drugs is now available under the brand names Rezolsta or Prezcobix). Clinical trials showed that cobicistat/darunavir is as safe and effective as ritonavir-boosted darunavir. Ritonavir has been associated with significant drug interactions and side-effects, including lipid abnormalities. Protease inhibitors boosted by ritonavir are a risk factor for the development of cardiovascular disease, which is a major cause of illness and death in people with HIV. The effect on lipids of switching from ritonavir to cobicistat has received little attention.

This study

Investigators in Spain designed a retrospective, observational study examining changes in lipids after replacement of ritonavir with cobicistat as the boosting agent for darunavir. The study population consisted of 299 people who made this treatment change between December 2015 and May 2016. Fasting lipids were checked just before the treatment switch, and again six months later.

Hypercholesterolaemia was defined as total cholesterol above 200mg/dl and/or LDL ('bad') cholesterol above 130mg/dl, with hypertriglyceridaemia defined as triglyceride levels above 200mg/dl.

Overall, the median age was 49 years and 85% of the study participants were men. Just under half were taking darunavir/ritonavir monotherapy, with 9% receiving darunavir/ritonavir bitherapy and 41.5% triple-drug ART. All the study participants had an undetectable viral load and median CD4 cell count was 643 cells/mm3. The majority of individuals (52%) had abnormal lipids.

Viral control and CD4 count were unaffected by the treatment change.

Analysis of the entire study population showed that replacing ritonavir with cobicistat had no significant effect on cholesterol, though a significant decline was observed in median triglyceride levels (p = 0.018).

Restricting analysis to people with lipid abnormalities at baseline, showed significant falls in total cholesterol (p < 0.001), LDL cholesterol (p = 0.047), increases in HDL or good cholesterol (p = 0.002), and a decline in trigylcerides (p < 0.001).

The observational design of the study meant that the authors were not able to exclude other possible causes for these lipid changes, such as diet and exercise. And the percentage of people on boosted-darunavir monotherapy is much higher than it would be in some other countries. Further prospective randomised studies are therefore needed. Nevertheless, the investigators were encouraged by their findings.

“This exploratory analysis provides, for the first time, descriptive results demonstrating the beneficial impact on the lipid profile that cobicistat seems to have when it is used as a booster/pharmaco-enhancer of darunavir in HIV-1 infected subjects,” conclude the authors. “In addition, this new co-formulation makes the compound easier to take, thus improving adherence.”


Echeverría P et al. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia. HIV Med. Online edition. DOI: 10.1111/hiv.12530 (2017).



Find details of HIV services in Spain, the latest news from the country, and a selection of resources from local organisations.

Find out more about Spain >

Related news selected from other sources

More editors' picks on side-effects >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.